@article{2b03296a40be4efe8c401b210c212759,
title = "Current multidisciplinary management of brain metastases",
abstract = "Brain metastasis (BM), the most common adult brain tumor, develops in 20% to 40% of patients with late-stage cancer and traditionally are associated with a poor prognosis. The management of patients with BM has become increasingly complex because of new and emerging systemic therapies and advancements in radiation oncology and neurosurgery. Current therapies include stereotactic radiosurgery, whole-brain radiation therapy, surgical resection, laser-interstitial thermal therapy, systemic cytotoxic chemotherapy, targeted agents, and immune-checkpoint inhibitors. Determining the optimal treatment for a specific patient has become increasingly individualized, emphasizing the need for multidisciplinary discussions of patients with BM. Recognizing and addressing the sequelae of BMs and their treatment while maintaining quality of life and neurocognition is especially important because survival for patients with BMs has improved. The authors present current and emerging treatment options for patients with BM and suggest approaches for managing sequelae and disease recurrence.",
keywords = "brain metastases, immunotherapy, laser-interstitial thermal therapy, radiation therapy, radionecrosis, stereotactic radiosurgery",
author = "Moravan, {Michael J.} and Fecci, {Peter E.} and Anders, {Carey K.} and Clarke, {Jeffrey M.} and Salama, {April K.S.} and Adamson, {Justus D.} and Floyd, {Scott R.} and Torok, {Jordan A.} and Salama, {Joseph K.} and Sampson, {John H.} and Sperduto, {Paul W.} and Kirkpatrick, {John P.}",
note = "Funding Information: Peter E. Fecci reports research funding and personal fees from Monteris outside the submitted work. Carey K. Anders reports clinical trials support from Eli Lilly, G1‐Therapeutics, Merck & Company, Nektar, PUMA, Seattle Genetics, and Tesaro; and personal fees from Eisai, Genentech/Roche, Ipsen, and PUMA, all outside the submitted work. Jeffrey M. Clarke reports research funding and nonfinancial support from Bristol‐Myers Squibb outside the submitted work; research funding, personal fees, and nonfinancial support from Eli Lilly outside the submitted work; research funding from AbbVie, Adaptimmune, Array, Bayer, Bristol‐Myers Squibb, Eli Lilly, Genentech, GlaxoSmithKline, Medpacto, Moderna, and Spectrum; personal fees, nonfinancial support, and travel expenses from Eli Lilly, Guardant, and Merck & Company; personal fees from Achilles Therapeutics; and serves on the Lung Cancer Initiative of North Carolina board of directors (uncompensated), all outside the submitted work. April K. S. Salama reports personal fees from Array and Bristol‐Myers Squibb and institutional research funding from Bristol‐Myers Squibb, Celldex, Dynavax, Immunocore, Merck & Company, and Reata, all outside the submitted work. Justus D. Adamson reports ownership interest in Clearsight RT, LLC. John H. Sampson reports grants and personal fees from Annias Immunotherapeutics; owns equity in Immunomic Therapeutics and Insera Health; owns intellectual property with Celldex; and patents with Instarl and Neuronium, all during the course of the study. John P. Kirkpatrick reports research funding from Varian Medical Systems outside the submitted work and ownership interest in Clearsight RT, LLC. The remaining authors made no disclosures. Publisher Copyright: {\textcopyright} 2020 American Cancer Society",
year = "2020",
month = apr,
day = "1",
doi = "10.1002/cncr.32714",
language = "English",
volume = "126",
pages = "1390--1406",
journal = "Cancer",
issn = "0008-543X",
number = "7",
}